Chemed has spent 2026 turning a hospice crisis into a growth story, raising its full-year earnings outlook three times as VITAS shook off the Florida Medicare-cap problem that hobbled it last year. The stock has not followed along. Shares have slipped about 2% since the last report while the S&P 500 gained roughly 3%, which sets up a third-quarter release where the question is less whether the recovery is real and more whether it still has room to surprise.

The Street is looking for non-GAAP earnings of $6.39 per share on revenue of about $680.1 million, an 8.8% increase from a year ago. Against year-ago earnings of $4.94, that implies growth of roughly 29%, a strong figure that reflects how depressed last year's comparison was. The Earnings Whisper sits slightly higher at $6.45, a modest gap that hints at a quiet expectation for another beat rather than a dramatically elevated bar. More telling is the full-year picture: management now guides to $25.00 to $25.75 per share, yet the consensus annual estimate of $24.42 sits below the bottom of that range. Either estimates have lagged the latest raise or analysts remain unconvinced, and a clean quarter could force a round of upward revisions.

VITAS is where the guidance is earned. Average daily census growth reached 6.1% last quarter, up from 2.2% in the first quarter, and total census topped 24,000 for the first time. Management lifted its census growth target to 5.75% to 6.25% and pushed its ex-cap margin goal to 19% to 19.5%. Validation this quarter means census growth holding near or above 6%, admissions from the newer Florida counties of Marion, Pasco, Pinellas and Manatee continuing to build, and segment EBITDA growth staying well into double digits after last quarter's 20.6% jump. Management also cut its expected full-year cap limitation to $7 million and anticipates nothing from Florida, so any renewed cap accrual, or a step back in California where referral sources have been gravitating toward trusted providers amid a fraud crackdown, would undercut a central pillar of the bull case.

Roto-Rooter is the counterweight. Its adjusted EBITDA was flat last quarter, margin slipped 77 basis points to 21.1%, and the segment missed its own internal target by about $1 million, all on marketing. Paid leads now make up 59% of the total as free search traffic erodes, a shift management treats as permanent. Full-year guidance of 3% to 3.5% revenue growth and a 21.5% to 22.5% margin was held steady, already lowered from the original outlook. The tests here are whether internet marketing costs have stabilized as promised, whether water restoration revenue declines keep narrowing as billing centralization matures, and whether roughly $33.5 million of first-half franchise acquisitions begin to add visible revenue.

Sentiment has improved notably, with the bearish reading easing from about 19.5% to 4.4%, so the crowd is far less skeptical than it was a quarter ago. Technically, the stock trades near $512, comfortably above its 200-day average of about $459 but in the lower half of its post-earnings range of roughly $492 to $557. That positioning suggests the market has banked the recovery without paying up for further upside.

Ultimately, this report hinges on whether VITAS can sustain its double-digit earnings growth with cap risk neutralized while Roto-Rooter's marketing drag stays contained. Steady census gains and a reaffirmed or raised outlook would argue the stock's recent lag is an opportunity; any sign that hospice momentum is plateauing would suggest the guidance raises have already captured the good news.